login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
OCUGEN INC (OCGN) Stock News
NASDAQ:OCGN -
US67577C1053
-
Common Stock
1.045
USD
+0.01 (+1.46%)
Last: 9/10/2025, 1:13:41 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
OCGN Latest News, Press Relases and Analysis
All
Press Releases
8 days ago - By: Ocugen
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
8 days ago - By: Ocugen
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
15 days ago - By: Zacks Investment Research
Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know
a month ago - By: Ocugen
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
a month ago - By: Benzinga
Demystifying Ocugen: Insights From 5 Analyst Reviews
a month ago - By: The Motley Fool
Ocugen (OCGN) Q2 Revenue Jumps 20%
a month ago - By: Benzinga
A Peek at Ocugen's Future Earnings
a month ago - By: Ocugen
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
a month ago - By: Ocugen
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
a month ago - By: Ocugen
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
a month ago - By: Ocugen
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
a month ago - By: Ocugen
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
a month ago - By: Zacks Investment Research
- Mentions:
CCCC
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
a month ago - By: Ocugen
Ocugen Provides Business Update with Second Quarter 2025 Financial Results
a month ago - By: Ocugen
Ocugen Provides Business Update with Second Quarter 2025 Financial Results
2 months ago - By: Ocugen
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
2 months ago - By: Ocugen
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
2 months ago - By: Ocugen
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
2 months ago - By: Ocugen
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
2 months ago - By: Ocugen
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
2 months ago - By: Ocugen
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
3 months ago - By: Brodsky & Smith LLC
- Mentions:
CARM
GNTY
GBCI
MRC
...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)
3 months ago - By: Ocugen
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
3 months ago - By: Ocugen
- Mentions:
CARM
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
3 months ago - By: Ocugen
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
3 months ago - By: Ocugen
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
3 months ago - By: Ocugen
Ocugen To Present at BIO International Convention 2025
3 months ago - By: Ocugen
Ocugen To Present at BIO International Convention 2025
3 months ago - By: Ocugen
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
3 months ago - By: Ocugen
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
4 months ago - By: Ocugen
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease
4 months ago - By: Ocugen
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease
Please enable JavaScript to continue using this application.